STOCK TITAN
  1. Home
  2. News
  3. PACB

Pacific Biosciences of California Inc - PACB STOCK NEWS

Welcome to our dedicated news page for Pacific Biosciences of California (Ticker: PACB), a resource for investors and traders seeking the latest updates and insights on Pacific Biosciences of California.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Pacific Biosciences of California's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Pacific Biosciences of California's position in the market.

News
TurnCare, Inc. Announces John F. Milligan, PhD, former CEO of Gilead Sciences, joins Board of Directors
Rhea-AI Summary
TurnCare, a leading medical technology and services company dedicated to advancing how hospitals manage high acuity patients, proudly announces the addition of John F. Milligan, Ph.D., investor, innovator, and former CEO of Gilead, to its Board of Directors. Dr. Milligan's expertise includes driving major acquisitions to create unique industry solutions and scaling Gilead to over $21 Billion in worldwide sales with a market cap of $85 Billion. He brings a unique and valuable perspective that will help TurnCare maximize the impact of its novel patient management technologies as it scales to more networks, hospitals, and patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.78%
Tags
management
-
News
PacBio Announces Record Preliminary Fourth Quarter and Full Year Revenue Growing 113% and 56%, respectively
Rhea-AI Summary
PacBio (PACB) achieved record revenue in 2023, with $58.4 million in Q4 and $200.5 million for the full year. The company shipped 44 Revio sequencing systems and 20 Sequel IIe systems, with a total installed base of 173 and 532 systems, respectively. Preliminary consumable revenue for Q4 was $18.9 million, with approximately 67% from Revio. PacBio aims for annual revenue growth of 40-50% through 2026, targeting over $500 million in 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.51%
Tags
none
-
News
PacBio to Present at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
PacBio (NASDAQ: PACB) to present at 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.68%
Tags
conferences
News
PacBio Announces the Retirement of David Botstein, Ph.D., from its Board of Directors
Rhea-AI Summary
PacBio (NASDAQ: PACB) announced the retirement of David Botstein, Ph.D., a member of PacBio's Board of Directors, effective December 7, 2023. Christian Henry, President and CEO, expressed gratitude for Botstein's contributions to the company's technological innovation and leadership.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.33%
Tags
management
-
News
PacBio to Present at Upcoming Investor Conferences
Rhea-AI Summary
PacBio (NASDAQ: PACB) to participate in upcoming investor conferences, including Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum and Piper Sandler 35th Annual Healthcare Conference. Live webcasts available on the company's investors page at investor.pacificbiosciences.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
News
PacBio Announces HiFi Solves, a Global Consortium of Clinical Genomics Research Leaders
Rhea-AI Summary
PacBio has announced the creation of the HiFi Solves consortium, which brings together researchers from 15 genomics research institutions across 11 countries. The consortium aims to study the value of HiFi-based human genome sequencing in clinical research and genetic diseases. Through collaboration, the consortium will develop and share best practices on data generated from PacBio Revio sequencing systems. The goal is to accelerate the global adoption of HiFi sequencing and potentially offer families solutions to their diagnostic odyssey.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.21%
Tags
none
News
PacBio Enables Rare and Inherited Disease Research by Adding Tertiary Analysis Partners to PacBio Compatible
Rhea-AI Summary
PacBio has partnered with two tertiary analysis partners to enhance PacBio Compatible, its sequencing solutions platform. The partnerships aim to maximize the value of HiFi data and complete the end-to-end workflow for PacBio customers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.4%
Tags
none
-
News
PacBio Announces Kinnex RNA Kits, Further Scaling HiFi Sequencing in Full-Length RNA, Single-Cell RNA and 16S rRNA Applications
Rhea-AI Summary
PacBio has introduced the Kinnex RNA kits, which increase throughput for full-length RNA, single-cell RNA, and 16S rRNA sequencing. The kits are based on the MAS-Seq method and offer cost-effective solutions for large-scale studies. The Kinnex single-cell RNA kit supports 10x Genomics 5' kit and library multiplexing. The Kinnex full-length RNA kit yields 40 million reads on the Revio system and 15 million reads on the Sequel II and IIe systems. The Kinnex 16S rRNA kit enables high-quality microbiome sequencing at any scale.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.08%
Tags
none
-
News
PacBio Announces Third Quarter 2023 Financial Results
Rhea-AI Summary
PacBio (NASDAQ: PACB) reported Q3 2023 financial results with revenue of $55.7 million, a 72% increase YoY. Gross profit increased by 32% to $17.9 million. Operating expenses totaled $100.4 million. Net loss for the quarter was $66.9 million, compared to $77.0 million in Q3 2022. Cash and investments totaled $767.8 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.08%
Tags
earnings
News
PacBio Announces Appointment of David Meline to Board of Directors
Rhea-AI Summary
Former CFO of Moderna, Amgen, and 3M, David Meline, joins PacBio Board of Directors
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
Stock PACB logo
Pacific Biosciences of California Inc

Nasdaq:PACB

PACB Rankings

#3223 Ranked by Market Cap
#3070 Ranked by Stock Gains
N/A Ranked by Dividends

PACB Stock Data

849.41M
266.44M
2.8%
101.74%
18.31%
Analytical Laboratory Instrument Manufacturing
Manufacturing
Link
United States
Menlo Park

About PACB

pacbio develops comprehensive solutions for scientists that propel the field of genomics, improve science and research, and create positive impact globally. we provide sophisticated genomic analysis systems that deliver invaluable insights for scientists who strive to resolve complex genetic challenges. our strength comes from the dedication of our people, who are fueled by a desire to effect real, positive change. with a focus on the future and an experienced, passionate team, we are motivated to continue to redefine what is possible in genomics.